Introduction
An extremely low fat, palatable elemental diet containing amino acids is commercially available in Japan where it is elemental diet in addition to intravenous fluid therapy (EN-IV group) from September 2013 to March 2016.
Study design
This is a case-control pilot study, based on historical comparisons of patients in two time periods, with data being collected retrospectively. The Institutional Review Board of this hospital approved the retrospective analyses. All enrolled patients reported the average number of bowel movements/per day to doctors and underwent blood testing at least once a week during induction therapy, irrespective of hospitalization. Each patient was told to record the number of bowel movements/ per day before the start of induction therapy. The determination of defecation frequency and clinical response outcomes was based on a retrospective review of the patients' charts with special attention to clinical symptom and the laboratory data before and after induction therapy. The frequency of defecation and clinical response outcomes were retrospectively compared in both groups before and on day 14 after the first infusion of infliximab (5 mg/kg) [12, 13, 14] . Endoscopic and histological examinations were performed within 1 week before and 2-4 weeks after the start of the induction therapy. Disease activity was defined according the endoscopic Mayo Score [12, 13] and Simple Clinical Colitis Activity Index [14] . Clinical response was decided as a total score of Simple Clinical Colitis Activity Index ≤4 points on day 14 after the first infusion of infliximab. Based on these results it was decided whether the second infusion of infliximab would be required. Data required for calculation of the activity scores were prospectively recorded.
Elemental diet used
A commercially available predigested elemental diet, Elental® (1 kcal/mL, EA Pharma Co., Ltd., Tokyo, Japan) consisting of 16.5% protein (provided as amino acids), 79.5% carbohydrates (provided as dextrin, mean molecular weight 900), 0.64% fat, and 3.36% vitamins and minerals dissolved in water to yield 1 kcal/mL was used.
Diet and fluid therapy
The IV group received peripheral IV fluid therapy (Na
75 g/L) (840 kcal/2000 mL/day-1050 kcal/2500 mL/ day) with intake of only liquids (tea or sport beverages) for the first week and then received a low residue diet (800-1000 kcal/ day) with tapering of the amount of IV fluid during the second week. All patients in this group were hospitalized for at least one week.
In EN-IV group all patients received the orally administered elemental diet (Elental®) for at least 7 days with intake of only liquids and then received low residue diet or regular diet (800-1000kcal/day) for the second week, irrespective of hospitalization. In the EN-IV group 11 patients also received IV fluids (210 kcal/500mL/day) for 1 to 4 days in the outpatient clinic. The remaining 5 patients were hospitalized and received IV fluid therapy (420 kcal/1000 mL/day) for 7 days. All patients in the two groups were scheduled to receive the total calorie of 800-1000 kcal/day for two weeks after the start of induction therapy. The estimated total calorie intake/day for 2 weeks after the start of induction therapy was calculated for each patient. Twelve hospitalized patients of the two groups received intravenous antibiotics. No steroids, immunosuppressive drugs, or anti-motility drugs were administered.
Statistics
The study size is based on a comparison of patients from two consecutive time periods. Data was collected retrospectively. All data are expressed as median (Interquartile range). Statistical tests to compare the measured results for the two groups were as follows: the Chi-square test, with Yates' correction for continuity where appropriate, was used for comparison of categorical data. Fisher's exact test was used when the numbers were small. For nonparametric data, Mann-Whitney test was used when 2 means were compared. A paired t test was used to compare the parametric data before and after induction therapy in the two groups. Statistical analysis was performed by using SAS 9.2 (SAS Institute Japan).
Results
Twenty-eight patients were enrolled including 12 in the IV group. The EN-IV group included 16 patients. The patients' demographic characteristics were similar between the two groups ( Table 1) . Seven patients (58%) in the IV group and 13 patients (81%) in the EN-IV group achieved clinical response (total score of Simple Clinical Colitis Activity Index ≤4 points). Four patients (two in the IV group, two in the EN-IV group) who had no response underwent surgery while the remaining 4 patients (one in the IV group, three in the EN-IV group) were successfully remitted by tacrolimus. Elemental diet was orally taken four or six times/day and the total intake of elemental diet was [median (Interquartile range)] 900 (600-900) kcal/day for 8 (7-10) days (Table 1) . For two weeks after the start of induction therapy, the estimated total calorie intakes/day were similar in both groups [900(900-1000) vs. 1000(900-1062), P=0.25]. The duration of IV fluid and the duration of hospitalization in the EN-IV group were significantly shorter than those of the IV group, respectively [3.5 (1-7) vs. 9 (7-15.8), P<0.0001; 0 (3.5-9.3) days vs. 8(15-21) days, P=0.0012 (Table 1) .
When clinical data was compared between before and after induction therapy, stool frequency, endoscopic Mayo Score, and Simple Clinical Colitis Activity Index were all significantly reduced in both groups following the first infusion of infliximab (Fig.1abc) . Serum albumin level was maintained in the EN-IV group whereas it was significantly reduced in the IV group 2 weeks after initiation of induction therapy (Fig.1d) . The hemoglobin significantly remained unchanged in both groups (data not shown). C-reactive protein value was significantly reduced after induction therapy in both groups. When clinical data was compared between two groups before and 2 weeks after the first infusion of infliximab, stool frequency in EN-IV group was less than that of IV group [3 (2.3-3.8) vs. 4.5 (2.8-6.8), P=0.073] ( Table 2) receiving elemental diets was maintained significantly higher than that in the IV group during induction therapy [3.9 (3.5-4.2) vs. 3.2 (3-3.5), P=0.0039]. C-reactive protein level decreased similarly in the two groups, but the difference was not significant.
Discussion
This pilot study suggests that the addition of orally administered elemental diets can significantly shorten the duration of hospitalization when used with infliximab induction therapy for ulcerative colitis compared to use of IV fluids alone (Table 1 ). In addition, use of an orally administered elemental diet was associated with an improved clinical response and maintenance of serum albumin levels compared with IV therapy alone during induction therapy with infliximab (Table 2) .
Although infliximab, a chimeric monoclonal antibody against tumor necrosis factor alpha is an effective therapy for introduction and maintenance of remission in ulcerative colitis [15] , a significant percentage of patients who respond initially experience loss of response during therapy. On proposed mechanism is related to loss of infliximab into feces in patients with moderate-to-severe ulcerative colitis [10] demonstrated even if elemental diet seemed to have a beneficial effect on the stage of clinical activity, especially diarrhea, in patients with ulcerative colitis [16] . However, the results of this study suggest that elemental diet may have some inhibitory effects on inflammation in patients with active ulcerative colitis. The effects of elemental diet composed of amino acids might be due to lowering of the antigenicity of the luminal contents attributed in part to the absence of whole protein, alteration of host bacterial flora, and decreasing colonic fecal bile salt load [3, 4] .
In previous studies, a rationale for nutritionally supporting patients with active inflammatory bowel disease has been provided [17] . Patients with mild to moderate attacks can be managed with an oral conventional diet. It is recommended that no major dietary restrictions should be prescribed in active disease, except for avoidance of coarse fiber (particularly in patients with ulcerative colitis, and in the presence of bowel strictures in Crohn's disease). On the other hand, dietary restrictions are traditionally apt to be given patients with diarrhea and peripheral IV therapy is preferable in Japan. However, the estimated total calorie intakes/day were similar in both groups for two weeks after the start of induction therapy ( Table 1 ).
The elemental diet (Elental®) used here is a high osmolality nutrient (1 kcal/mL equals 760 mOsm/L) and is typically given at <100 mL/h using a pump when used for treatment of patients with Crohn's disease in Japan. However, when the elemental diet was fed at the rate of 200-300 mL/h to gastrostomy-fed patients diarrhea did not occur in any patient [7] . A different elemental diet with the same high osmolality has been shown to be well tolerated when given intragastrically without a starter solution in patients with inflammatory bowel disease [18] . In this study, the EN-IV group had lower stool frequency compared with those in the IV group during induction therapy [3 (2.3-3.8) vs. 4.5 (2.8-6.8), P=0.073] ( Table 2 ).
The present studies have limitations. The study was a pilot case-control study with the small number of patients. The selection of case or control was decided based on the entry period. So we believe this study is unlikely to have critical bias to the patient selection. However, randomized studies will be required to confirm the beneficial effects of oral ingestion of elemental diet during induction therapy in patients with ulcerative colitis. The total number of calories administered during traditional Japanese therapy was less than recommended in western publications. Studies are needed to evaluate the effect of increasing the total volume and thus number of calories administered as well as direct comparison with traditional liquid nutritional supplements. This pilot study brings up many questions and additional studies are needed to confirm and extend these observations. For example, studies are need to ask whether oral use of an elemental diet can substitute for IV fluid therapy during induction therapy with infliximab which would reduce the need for hospitalization in patients with ulcerative colitis. Finally, studies are needed to identify the best time to switch from the elemental diet to standard diet after induction therapy. clearance is also significantly increased by low serum albumin level, resulting in short half-life and decreased troughs of infliximab [11] . This study showed that oral elemental diet therapy during induction therapy prevented the decrease in serum albumin levels which may be in part responsible for the better clinical response outcomes in the EN-IV group than those of the IV group. In addition, oral ingestion of elemental diet during induction therapy enabled patients with moderate-tosevere ulcerative colitis to reduce the duration of hospitalization.
Elemental diet feeding has been reported to remit Crohn's disease in Japanese patients [3] . Because the beneficial effects of elemental diet were thought to have an anti-inflammatory effect for the small intestine but not the large intestine, elemental diets were not used for patients with ulcerative colitis [8] . In addition, it was reported that an effect on inflammation could not be Citation: Horiuchi 
Conclusion
In conclusion, this study suggests that oral ingestion of an elemental diet resulted in a reduction in hospitalization, and an improved clinical response and serum albumin level compared with IV fluid therapy during induction therapy with infliximab for ulcerative colitis.
